Yahoo
NasdaqCM - BOATS Real Time Price USD

BioRestorative Therapies, Inc. (BRTX)

0.2017 +0.0044 (+2.23%)
At close: September 2 at 4:00:01 PM EDT
0.1687 -0.0330 (-16.36%)
Overnight: 8:38:35 PM EDT
Chart Range Bar
Loading chart for BRTX
Chart does not reflect overnight price.
  • Previous Close 0.1973
  • Open 0.2030
  • Bid 0.1400 x 200
  • Ask 0.2613 x 200
  • Day's Range 0.2007 - 0.2099
  • 52 Week Range 0.1593 - 1.7300
  • Volume 123,436
  • Avg. Volume 480,880
  • Market Cap (intraday) 5.139M
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0600
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.00

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

www.biorestorative.com

13

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BRTX
82.83%
S&P 500 (^GSPC)
11.99%

1-Year Return

BRTX
88.34%
S&P 500 (^GSPC)
19.50%

3-Year Return

BRTX
91.23%
S&P 500 (^GSPC)
69.77%

5-Year Return

BRTX
98.80%
S&P 500 (^GSPC)
68.98%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 23.17k
Earnings -2.15M
Profit Margin -9,298.25%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-3M
-2M
-1M
0
-25000.0%
-20000.0%
-15000.0%
-10000.0%
-5000.0%

Analyst Insights

View More

Analyst Price Targets

1.00
8.00 Average
0.2017 Current
15.00 High

Latest Rating

Date 8/14/2024
Analyst Roth MKM
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 15 -> 18

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    5.05M

  • Enterprise Value

    -7.98M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.28

  • Price/Book (mrq)

    1.67

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -118.81%

  • Return on Equity (ttm)

    -241.14%

  • Revenue (ttm)

    357.87k

  • Net Income Avi to Common (ttm)

    -11.06M

  • Diluted EPS (ttm)

    -1.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.59M

  • Total Debt/Equity (mrq)

    0.95%

  • Levered Free Cash Flow (ttm)

    -9.71M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.2017 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: